All News

Sure, prescription information for Sanofi-Aventis's Uroxatral appears on the back of the tent card, but how can consumer?s see it if it's mounted to a pharmacy wall?

28 October

bill Campbell

The US oversight arm scripted a hefty report complaining that FDA is not moving fast enough when it comes to screening clinical trials data for drugs green lit through its expedited approval program.

US-based CRO, Health Decisions, hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs.

The third quarter reports are in, and Pfizer's profits are up but sales are down. The company is compensating for looming patent expirations with layoffs and restructuring; is it enough to boost sales?

21 October

Industry Audit and Company of The year.

Cegedim CEO Laurent Labrune talks to Pharm Exec Europe about how the company is maintaining its CRM lead in a rapidly changing industry.

19 October

Professional Scientific StaffingSM Solutions - Lancaster Whitepaper

PharmRep 2010 sworn statement

Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development.

GSK is being ordered to pay $2.5 million in restitution to a Pennsylvania family. The firm was accused of not doing enough to warn consumers that taking the antidepressant Paxil, while pregnant, could lead to birth defects.

Sandoz Shire Pharmaceuticals announced that it would allow Sandoz to market a generic version of its blockbuster ADHD med Adderall XR if it can clear FDA. But that's a big if.

13 October

12 October

Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates.

Meet Pharm Exec?s 2009 Emerging Leaders?27 industry pioneers under age 45 who are bringing new ideas to life - 09 emerging leaders

Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe?

Pharm Exec Europe speaks to Cellectis CEO André Choulika about the biotech company's ongoing success and the advantages of being based in France.